FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript

Listens: 0

About

The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Transcript

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

February 28, 2020

Science

The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Transcript